ACADIA Pharmaceuticals Net Worth
ACADIA Pharmaceuticals Net Worth Breakdown | ACAD |
ACADIA Pharmaceuticals Net Worth Analysis
ACADIA Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ACADIA Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ACADIA Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ACADIA Pharmaceuticals' net worth analysis. One common approach is to calculate ACADIA Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ACADIA Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ACADIA Pharmaceuticals' net worth. This approach calculates the present value of ACADIA Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ACADIA Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ACADIA Pharmaceuticals' net worth. This involves comparing ACADIA Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ACADIA Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if ACADIA Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ACADIA Pharmaceuticals' net worth research are outlined below:
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investors.com: ACADIA Pharmaceuticals Earns RS Rating Upgrade |
ACADIA Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ACADIA Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ACADIA Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know ACADIA Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ACADIA Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ACADIA Pharmaceuticals backward and forwards among themselves. ACADIA Pharmaceuticals' institutional investor refers to the entity that pools money to purchase ACADIA Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Trust Advisors L.p. | 2024-12-31 | 2.7 M | Sg Americas Securities, Llc | 2024-12-31 | 2.5 M | Point72 Asset Management, L.p. | 2024-12-31 | 2.2 M | Citigroup Inc | 2024-12-31 | 1.7 M | Tang Capital Management Llc | 2024-12-31 | 1.5 M | Norges Bank | 2024-12-31 | 1.4 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.3 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | Baker Bros Advisors Lp | 2024-12-31 | 42.9 M | Vanguard Group Inc | 2024-12-31 | 13.9 M |
Follow ACADIA Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.8 B.Market Cap |
|
Project ACADIA Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.21 | 0.22 | |
| Return On Capital Employed | 0.29 | 0.31 | |
| Return On Assets | 0.19 | 0.20 | |
| Return On Equity | 0.31 | 0.32 |
When accessing ACADIA Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ACADIA Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ACADIA Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of ACADIA Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.
Evaluate ACADIA Pharmaceuticals' management efficiency
ACADIA Pharmaceuticals has return on total asset (ROA) of 0.0544 % which means that it generated a profit of $0.0544 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3889 %, meaning that it created $0.3889 on every $100 dollars invested by stockholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.31. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 82.8 M, whereas Net Tangible Assets are forecasted to decline to about 403.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.42 | 4.64 | |
| Tangible Book Value Per Share | 3.70 | 3.88 | |
| Enterprise Value Over EBITDA | 27.69 | 29.07 | |
| Price Book Value Ratio | 4.15 | 4.46 | |
| Enterprise Value Multiple | 27.69 | 29.07 | |
| Price Fair Value | 4.15 | 4.46 | |
| Enterprise Value | 1.7 B | 1.8 B |
Evaluating the management effectiveness of ACADIA Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The ACADIA Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 2.1905 | Revenue | Quarterly Revenue Growth 0.124 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ACADIA Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ACADIA Pharmaceuticals Corporate Filings
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 27th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
ACADIA Pharmaceuticals Earnings per Share Projection vs Actual
ACADIA Pharmaceuticals Corporate Management
| Parag PharmD | Senior Franchise | Profile | |
| Bob Mischler | Senior Strategy | Profile | |
| Douglas MD | Executive Development | Profile | |
| James Kihara | Senior Finance | Profile | |
| Rob Ackles | Senior Officer | Profile |
Already Invested in ACADIA Pharmaceuticals?
The danger of trading ACADIA Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ACADIA Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ACADIA Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ACADIA Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.133 | Earnings Share 1.36 | Revenue Per Share | Quarterly Revenue Growth 0.124 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.